Fulgent Genetics (FLGT) Projected to Post Earnings on Friday

Fulgent Genetics (NASDAQ:FLGT) will likely be posting its quarterly earnings results before the market opens on Friday, February 28th. Analysts expect Fulgent Genetics to post earnings of ($0.31) per share and revenue of $75.39 million for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.

Fulgent Genetics Stock Down 0.3 %

Shares of FLGT stock opened at $16.24 on Thursday. Fulgent Genetics has a twelve month low of $15.99 and a twelve month high of $25.48. The company has a market cap of $496.73 million, a P/E ratio of -2.94 and a beta of 1.39. The business has a fifty day simple moving average of $17.43 and a 200 day simple moving average of $19.58.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. Piper Sandler dropped their price objective on Fulgent Genetics from $26.00 to $22.00 and set a “neutral” rating for the company in a research report on Monday, November 11th. StockNews.com cut Fulgent Genetics from a “hold” rating to a “sell” rating in a report on Wednesday, November 27th.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.